Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 25
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.72%
|
$89,000
$89.55 P/Share
|
|
Apr 24
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
937
-1.28%
|
$87,141
$93.0 P/Share
|
|
Apr 23
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,523
-2.04%
|
$138,593
$91.38 P/Share
|
|
Apr 23
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,552
-1.1%
|
$232,232
$91.38 P/Share
|
|
Apr 23
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
522
-0.47%
|
$47,502
$91.38 P/Share
|
|
Apr 23
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
531
-0.45%
|
$48,321
$91.38 P/Share
|
|
Apr 23
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
787
-0.38%
|
$71,617
$91.38 P/Share
|
|
Apr 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.65%
|
-
|
|
Apr 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+1.54%
|
-
|
|
Apr 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.76%
|
-
|
|
Apr 21
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.31%
|
-
|
|
Apr 21
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
143
+0.04%
|
-
|
|
Apr 20
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,521
+2.06%
|
-
|
|
Apr 20
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+1.44%
|
-
|
|
Apr 20
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.41%
|
-
|
|
Apr 20
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
190
+0.06%
|
-
|
|
Apr 16
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
80,000
-22.35%
|
$7,200,000
$90.7 P/Share
|
|
Apr 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,816
-0.98%
|
$633,888
$93.67 P/Share
|
|
Apr 03
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
26,700
-2.63%
|
$2,456,400
$92.49 P/Share
|
|
Apr 02
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,378
-1.91%
|
$126,776
$92.62 P/Share
|
|
Mar 28
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
914
-1.25%
|
$82,260
$90.42 P/Share
|
|
Mar 28
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,662
-1.12%
|
$239,580
$90.42 P/Share
|
|
Mar 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
464
-0.41%
|
$41,760
$90.42 P/Share
|
|
Mar 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
707
-0.36%
|
$63,630
$90.42 P/Share
|
|
Mar 28
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
743
-0.36%
|
$66,870
$90.42 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.71%
|
$90,000
$90.13 P/Share
|
|
Mar 28
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
447
-0.06%
|
$40,230
$90.27 P/Share
|
|
Mar 27
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,292
+3.05%
|
-
|
|
Mar 27
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
5,184
+2.14%
|
-
|
|
Mar 27
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,364
+0.66%
|
-
|
|
Mar 27
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
447
+0.13%
|
-
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Indirect |
50,910
-56.93%
|
$4,480,080
$88.85 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
83,223
-9.68%
|
$7,323,624
$88.86 P/Share
|
|
Mar 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
68,270
+7.22%
|
$1,297,130
$19.58 P/Share
|
|
Mar 15
2024
|
Roelof Botha Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,924
+15.53%
|
$896,580
$45.64 P/Share
|
|
Mar 07
2024
|
Jonathan Sheena |
BUY
Bona fide gift
|
Indirect |
110,854
+44.16%
|
-
|
|
Mar 07
2024
|
Jonathan Sheena |
SELL
Bona fide gift
|
Direct |
110,854
-24.17%
|
-
|
|
Mar 06
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
5,000
-0.54%
|
$440,000
$88.79 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
190,000
-4.79%
|
$16,720,000
$88.1 P/Share
|
|
Mar 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
1,012
-0.05%
|
$88,044
$87.81 P/Share
|
|
Mar 05
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
1,838
-0.8%
|
$159,906
$87.86 P/Share
|
|
Mar 05
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
2,245
-0.56%
|
$195,315
$87.85 P/Share
|
|
Mar 05
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,826
-3.85%
|
$248,688
$88.36 P/Share
|
|
Mar 05
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
9,326
-3.64%
|
$820,688
$88.36 P/Share
|
|
Mar 05
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,160
-1.05%
|
$190,080
$88.36 P/Share
|
|
Mar 05
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
1,028
-0.22%
|
$90,464
$88.36 P/Share
|
|
Mar 01
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,400
+2.12%
|
-
|
|
Mar 01
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
2,329
+1.17%
|
-
|
|
Mar 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,826
+3.7%
|
-
|
|
Mar 01
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
9,326
+3.51%
|
-
|